Improving anti-trypanosomal activity of alkamides isolated from Achillea fragrantissima by Skaf, Joseph et al.
Contents lists available at ScienceDirect
Fitoterapia
journal homepage: www.elsevier.com/locate/ﬁtote
Improving anti-trypanosomal activity of alkamides isolated from Achillea
fragrantissima
Joseph Skafa, Omar Hamarshehb, Michael Berningera, Srikkanth Balasubramanianc,
Tobias A. Oelschlaegerc, Ulrike Holzgrabea,⁎
aUniversity of Würzburg, Institut für Pharmazie und Lebensmittelchemie, Am Hubland, 97074 Würzburg, Germany
bAl-Quds University, Faculty of Science & Technology, Department of Biology, P.O. Box 51000, Jerusalem, Palestine
cUniversity of Würzburg, Institut für Molekulare Infektionsbiologie, Josef-Schneider-Str. 2/D15, D-97080 Würzburg, Germany







A B S T R A C T
In previous studies the aerial parts of Achillea fragrantissima were found to have substantial antileishmanial and
antitrypanosomal activity. A bioassay-guided fractionation of a dichloromethane extract yielded the isolation of
the essential anti-trypanosomal compounds of the plant. Seven sesquiterpene lactones (including Achillolide-A),
two ﬂavonoids, chrysosplenol-D and chrysosplenetine, and four alkamides (including pellitorine) were identi-
ﬁed. This is the ﬁrst report for the isolation of the sesquiterpene lactones 3 and 4, chrysosplenetine and the group
of alkamides from this plant. Bioevaluation against Trypanosoma brucei brucei TC221 (T.b brucei) using the
Alamar-Blue assay revealed the novel alkamide 13 to have an IC50 value of 40.37 μM. A compound library,
derived from the alkamide pellitorine (10), was synthesized and bioevaluated in order to ﬁnd even more active
substances. The most active compounds 26 and 27 showed activities in submicromolar concentrations and se-
lectivity indices of 20.1 and 45.6, respectively, towards macrophage cell line J774.1. Toxicity of 26 and 27 was
assessed using the greater wax moth Galleria mellonella larvae as an in vivo model. No signiﬁcant toxicity was
observed for the concentration range of 1.25–20 mM.
1. Introduction
Trypanosomiasis, also known as African sleeping sickness, is a
vector-borne protozoal disease caused by the trypanosoma subspecies
Trypanosoma brucei (T.b) gambiense and T.b. rhodesiense[1]. The infec-
tion is transmitted to humans mainly by the bite of an infected tsetse ﬂy
(Glossina genus), particularly in Sub-Saharan Africa [1–2]. The World
Health Organization (WHO) reported three major T.b. epidemics, the
ﬁrst between 1896 and 1906, the second in the 1920s, and the third in
the 1970s [3–4]. A report published in January 2017 estimated the
number of actual cases to be below 20,000 with further 65 million
people being at risk of infection [3].
The disease is characterized by two stages; the hemolymphatic stage
called stage 1, being a peripheral extracellular infection associated with
non-speciﬁc clinical symptoms, and stage 2 where the parasite crosses
the blood-brain barrier (BBB) and invades the central nervous system
(CNS). It causes severe symptoms including mental impairment, fever,
headache, and chronic encephalopathy. This is followed by somnolence
and death if left untreated [5–6]. Currently available treatments of
trypanosomiasis depend on the subspecies of the parasite and the stage
of infection. During the ﬁrst stage, pentamidine is the drug of choice to
treat T.b. gambiense, while suramin is used against T.b. rhodesiense. Both
substances are not able to cross the BBB; therefore, they are ineﬀective
during the second stage of the disease. In addition, they are associated
with signiﬁcant adverse eﬀects such as exfoliative dermatitis and renal
failure for suramin and diabetes mellitus and nephrotoxicity for pen-
tamidine [5].
In the late stage of the infection, three therapeutic options are
available. Melarsoprol, an organo-arsenic compound, is eﬀective
against both subspecies. It has, however, many undesirable side eﬀects
and can lead to fatal encephalopathic syndromes (3% to 10%) [3,5].
Eﬂornithine is a second therapeutic option and less toxic than mel-
arsoprol. Unfortunately, it is only eﬀective against T.b. gambiense. Both
compounds have to be administered intravenously. Nowadays, the
WHO recommends the application of a nifurtimox and eﬂornithine
combination therapy (NECT), because it simpliﬁes the treatment regime
of eﬂornithine alone by reducing the treatment period and the number
of daily doses. However, this combination is not eﬀective against T.b.
rhodesiense[5] and consequently, new eﬀective and less toxic drugs are
in demand [4,7].
https://doi.org/10.1016/j.ﬁtote.2017.11.001
Received 21 September 2017; Received in revised form 24 October 2017; Accepted 1 November 2017
⁎ Corresponding author.





Achillea fragrantissima (Af; Asteraceae) or Qaysum (Arabic name),
respectively, is a desert plant that has been used in traditional medicine
in the Middle East region since many years for the treatment of re-
spiratory diseases and gastrointestinal disturbances [8]. Bedouins use
the plant for preparing anti-diuretic drinks for the treatment of stomach
ailments and various infections, e.g. of the urinary tract [9]. Since a
preliminary screening of the dichloromethane extract of the aerial parts
of Achillea fragrantissima revealed anti-leishmanial and anti-trypano-
somal activity, a bioassay-guided fractionation was performed to un-
ravel the active compounds. One of these compounds could be identi-
ﬁed as pellitorine, an alkamide having a moderate antitrypanosomal
activity. Thus, a small library of alkamides was synthesized in order to
improve activity of this substance and to decrease cytotoxicity.
2. Experimental
2.1. General
All starting materials and reagents where purchased from Sigma
Aldrich, Schnelldorf, Germany, and TCI Chemicals, Eschborn, Germany.
NMR spectra were recorded on a Bruker Avance 400 Ultra Shield™
spectrometer (Bruker Biospin, Ettlingen, Germany) and a Bruker DMX
600 (Bruker, Karlsruhe, Germany) instrument which were calibrated
using the residual undeuterated solvent as an internal reference
(DMSO-d6: 1H 2.5 ppm, 13C 39.52 ppm; methanol‑d4: 1H 3.31 ppm and
4.78 ppm, 13C 49.00 ppm, cChloroform-d1: 1H 7.24 ppm, 13C
77.23 ppm). Coupling constants (J) are given in Hertz.
For determining the purity of all compounds, analytical HPLC was
conducted on a Shimadzu system (Hilden, Germany) equipped with a
DGU-20A3R degassing unit, a LC20AB liquid chromatograph, and a
SPD20A UV/Vis detector. The stationary phase was a Synergi fusion-RP
(150× 4.6 mm, 4 μm) column (Phenomenex, Aschaﬀenburg,
Germany). The following gradient elution was applied: solvent A: water
with 0.1% formic acid, solvent B: MeOH with 0.1% formic acid. Solvent
A from 0% to 100% in 13 min, then 100% A for 5 min, from 100% to
5% A in 1 min, and 5% A for 4 min. The ﬂow rate was set to 1.0 mL/
min. UV detection was performed at 254 nm. ESI mass spectral data
were acquired on a Shimadzu LCMS-2020 instrument (Hilden,
Germany). IR spectra were recorded on a Jasco FT/IR-6100 spectro-
meter with an ATR unit (Groß-Umstadt, Germany) at room tempera-
ture. Flash column chromatography was performed on an Interchim
Puri-Flash 430 instrument (Ultra Performance Flash Puriﬁcation) con-
nected to an Interchim Flash ELSD (Montluçon, France). Preparative
HPLC was performed using an Agilent 1100 preparative HPLC instru-
ment (Waldbronn, Germany) utilizing a semi-preparative Synergy 4 μm
MAX-RP 80A column 150× 10 mm (Phenomenex, Aschaﬀenburg,
Germany), fraction collector, and a multiple wavelength detector. The
following gradient was applied: solvent A: water, solvent B: acetoni-
trile. Separation method: solvent B 10% for 2 min, 10% to 30% B in
1 min, then to 100% B over 22 min and again to 10% B over 2 min.
Galleria mellonella at the ﬁnal larval stage were purchased from
Mouse Live Bait (Balk, The Netherlands).
2.2. Plant material
Seeds of Achillea fragrantissima were obtained from a suburb near
Homs, Syria. 100 seeds were planted in spring in a greenhouse of the
garden. The fully-grown plants were collected in summer and dried at
room temperature in shade for 20 days until constant weight (harvest
approx.700 g). The identity of the seeds and the grown plants was
veriﬁed by Dr. Hildebrandt and Dr. Vogg at the botanical garden,
University of Würzburg.
2.3. Extraction and isolation
The aerial parts of A. fragrantissima were powdered using a la-
boratory grinder. The pulverized plant material (100 g) was extracted
for 24 h at room temperature with dichloromethane by stirring. The
extract was ﬁltered, followed by complete drying in vacuo to give a
crude residue (1.96%). Fractionation of the extract was performed
using ﬂash chromatography with a hexane/ethyl acetate gradient
eluent, yielding 7 major fractions. After bio-evaluation of each fraction
in vitro against T.b. brucei using the Alamar-Blue assay [10], the active
fractions (F2–F7) (IC50 < 100 μg/mL) were sub-fractionated by means
of preparative HPLC yielding 13 compounds (Fig. 1). The structures of
isolated compounds were elucidated by means of NMR, infrared (IR),
and mass spectroscopy (MS).
2.4. Biological assays
2.4.1. Anti-trypanosomal assay
The fractions, the extracts, as well as isolated and synthesized
compounds were tested towards trypanosoma according to Räz et al.
[10] Trypomastigote forms of T.b. brucei laboratory strain TC221 were
cultivated in Balz medium. A deﬁned number of parasites (104 trypa-
nosomes per mL) was tested in 96-well plates against diﬀerent con-
centrations of the test substances in a ﬁnal volume of 200 μL (1% DMSO
in Balz medium). Positive (trypanosomes added to culture medium) and
negative controls (test substance without trypanosomes) were run with
each plate. The plates were incubated at 37 °C in an atmosphere of 5%
CO2. After 24 h additional 20 μL of Alamar-Blue was added to each well.
A reading was done at 48 h. Any eﬀect of the test substances was
quantiﬁed as IC50 values by linear interpolation of three diﬀerent
measurements. The activity of the test substances was measured by
Fig. 1. Bioassay-guided fractionation of the DCM extract of A. fragrantissima.
J. Skaf et al. )LWRWHUDSLD²

light absorption using a MR 700 microplate reader (Dynatech En-
gineering Ltd., Willenhall, UK) at a wavelength of 550 nm with a re-
ference wavelength of 630 nm.
2.4.2. Cytotoxicity assay
The experiments were carried out according to Hiltensperger et al.
[2] The macrophage cell line J774.1 was maintained in complete Click
RPMI medium. For the experimental procedures, cells were detached
from the ﬂasks using a rubber scraper and cell densities were adjusted
to having 2× 104 cells/mL. J774.1 macrophages were seeded into 96-
well plates and were incubated (37 °C, 5% CO2, 95% humidity) over-
night to allow attachment and recovery. A set of increasing con-
centrations (1, 2.5, 5, 10, 25, 50, 75, and 100 μM) of the tested com-
pounds (125 μL) and complete RPMI medium were transferred into the
cell culture plates and allowed to incubate for 24 h. After adding 10 μL
of the cell proliferation reagent WST-1, incubation was continued at the
same conditions. The plates were read after 30 min and 2 h, respec-
tively, at λ= 440 nm. Control experiments to evaluate the eﬀect of cell
density, incubation time, and DMSO concentration were performed.
Absorbance in the absence of any compounds was set as 100% of
growth control.
2.4.3. In vivo toxicity assay (Galleria mellonella larvae)
Toxicity assessment in Galleria mellonella was performed as de-
scribed previously by Gibreel and Upton [11] with minor modiﬁcations.
Larvae were used immediately upon arrival for toxicity evaluation ex-
periments and were considered healthy if they were clear in color and
free of any spots or pigmentation (weighing approximately
200–250 mg). Solutions of the test substances 26 and 27 having con-
centrations ranging from 1.25–20 mM were prepared in endotoxin-free
PBS + 10% DMSO (vehicle). 20 μL of test substance was injected in the
last left pro-leg of a larvae using insulin syringes (BD Micro-Fine™+ -
Demi). Ten larvae were used per group. Four control groups were in-
cluded in the experiment: one group received no injection, one group
was injected 20 μL of endotoxin-free PBS, one group was injected 20 μL
of vehicle control, and one group received 20 μL methanol as positive
control. All groups of larvae were incubated in the absence of light at
37 °C in Petri dishes. Larval survival rates were recorded every 24 h for
120 h. Larvae not responding to touch were scored dead and vice versa.
Finally, Kaplan-Meier survival curves were generated with GraphPad
Prism v 6.04 and statistical signiﬁcance of the curves was evaluated
using the Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon test
utilizing the software; p < 0.05, statistically signiﬁcant.
2.5. Synthesis procedures
2.5.1. General procedure A for synthesis of compounds 14–19 and 22–40
To a mixture of 1 equiv. of the corresponding carboxylic acid,
4 equiv. of trimethylamine, 1 equiv. of the corresponding amine in di-
chloromethane (10 mL), and 1 equiv. of propylphosphonic anhydride
solution (T3P®) was slowly added at 0 °C under Argon atmosphere. The
reaction mixture was allowed to warm to RT and was stirred for 5 h.
The reaction was diluted with dichloromethane (20 mL) and saturated
aqueous NaCl solution (30 mL). The aqueous layer was extracted 3
times with dichloromethane (90 mL). The combined organic layers
were dried over Na2SO4. The solvent was removed in vacuo.
2.5.2. General procedure B for synthesis of compounds 20 and 21
1 equiv. of the corresponding carboxylic acid and 5 equiv. of 4-
methylmorpholine (NMM) were dissolved in abs. dimethylformamide
(10 mL) at RT under Argon atmosphere. After cooling to 0 °C, 4 equiv.
of i-butyl chloroformiate were added and the mixture was stirred for
1 h. Then, 4 equiv. of the corresponding amine were added and the
mixture was stirred for additional 2 h at RT. The solvent was removed
in vacuo, and 20 mL of water were added. The aqueous solution was
extracted 3 times with ethyl acetate (150 mL). The combined organic
layers were dried over Na2SO4. The solvent was removed in vacuo.
2.5.3. Puriﬁcation of synthesized compounds
The puriﬁcation of all synthesized compounds 14–40 was per-
formed by means of ﬂash chromatography using a mixture of cyclo-
hexane and ethyl acetate (70: 30) as solvent system over 20 min for
compounds 14–19, and dichloromethane and methanol gradient (100:
0 to 85: 15) over 35 min for compounds 20–40.
The analytical and spectroscopic data of all compounds can be
found in the supplementary data.
3. Results and discussion
Initially, a dichloromethane extract of A. fragrantissima collected in
Palestine was screened using the corresponding Alamar-Blue assay [12]
revealing a substantial anti-leishmanial activity. The question arose
whether the extract would also show anti-trypanosomal activity to-
wards T.b. brucei. Therefore, seeds of A. fragrantissima were collected in
Homs, Syria, and planted in a greenhouse of the botanical garden of the
University of Würzburg. The plants were harvested in summer and
dried in shadow. The powdered aerial parts of A. fragrantissima were
extracted with dichloromethane and the extract was tested for its an-
titrypanosomal activity. Since a substantial anti-infective activity was
found, the extract was fractionated by means of ﬂash chromatography
to obtain 7 fractions. These fractions were again tested against T.b.
brucei. The most active fractions 2 to 7 were further fractionated each.
For the entire scheme of fractionation see Fig. 1.
3.1. Identiﬁcation of isolated compounds
As can be seen in Fig. 2, three groups of natural products were
found: seven sesquiterpene lactones 1–7, two ﬂavonoids 8 and 9, and
four alkamides 10–13 including a novel alkamide 13.
Whereas the sesquiterpene lactones 1, Achillolide-A 2, 5, 6, and 7
were reported previously being found in A. fragrantissima[13–14], the
natural products 3 and 4 have never been isolated from this plant
though they were previously found in A. afra[15] and A. luoviciana[16],
respectively. Compounds 5 and 6 were isolated as a mixture of two
epimeric lactones which have a diﬀerent conﬁguration of the hydroxyl
group at the carbon C-1 [17].
Flavonoids 8 and 9 were identiﬁed to be Chrysosplenol-D [18–19]
and Chrysosplenetine [20], respectively. Chrysosplenol-D has a hy-
droxyl group at C-3′, whereas Chrysosplenetine carries a methoxyl
group. This is the ﬁrst report of isolation of Chrysosplenetine from A.
fragrantissima.
Furthermore, four alkamides Pellitorine 10, 11, 12[21–22], and the
new alkamide 13 were isolated from the plant in small amounts. The
alkamides group has never been reported being present in A. fra-
grantissima. However, the alkamides 10, 11, and 12 were previously
found in A. ptarmica from the Asteraceae family [22].
The spectral data (NMR, MS, IR) of all isolated compounds, ses-
quiterpene lactones, ﬂavonoids, and alkamides, were in accordance
with their respective data reported in the literature.
3.2. Structure elucidation of compound 13
The new compound 13 was isolated from fraction 3 as a white solid
substance. NMR data exhibits the structure of an alkamide similar to the
known Pellitorine (10) (Fig. 2). MS-data (m/z: 238.10) hinted to an
additional oxygen atom. The 13C NMR spectrum displays a signal at
δ= 202 ppm which is not visible in DEPT, indicating the presence of a
ketone group. 1H NMR and COSY diagrams point to a conjugated diene
moiety at δ= 7.25 ppm (m, 2H, H-3, 4), 6.51 ppm (d, J= 14.9 Hz, 1H,
H-5), and 6.44 ppm (d, J= 14.5 Hz, 1H, H-2). The coupling constants
of 14.9 Hz and 14.5 Hz indicate a trans-conﬁguration of the protons of
each double bond. Furthermore, the analysis of the HMBC data (Fig. 3)
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conﬁrms the position of the carbonyl carbon δ= 202 ppm being at C6.
The IR spectrum shows one band at 3358 cm−1 indicating a secondary
amine and two bands at 1658 cm−1 (m) and 1632 cm−1 (s) indicating
two carbonyl groups corresponding to the amide group at position 1
and the ketone group at position 6, respectively. Therefore, the struc-
ture was assigned to (2E,4E)-N-isobutyl-6-oxodeca-2,4-dienamide
(Fig. 3).
3.3. Bio-evaluation of the isolated compounds
All isolated compounds were subjected to the evaluating their in
vitro activity against T.b. brucei using the corresponding Alamar-Blue
assay and Pentamidine as a reference [10]. The bioevaluation data of all
isolated compounds is reported in Table 1.
Sesquiterpene lactones 1, 2, 3, and 4, were quite active with IC50
values between 3 and 27 μM. The epimeric mixture of 5 and 6 showed
weak activity, whereas compound 7 was not active at all. Inspecting
structures of the active sesquiterpene lactones revealed that the com-
bination of two acetoxy groups and an enone Michael system is im-
portant for the activity of 1. In absence of either the Michael system
(cf.3 and 4), or of the acetoxy group at C-13 (see 2, 5, and 6) and of
both the Michael system and the acetoxy group, the activity is sub-
stantially reduced or completely lost as in 7.
This is the ﬁrst study on the anti-trypanosomal activity of these
particular sesquiterpene lactones. However, sesquiterpene lactones are
widely known to exhibit antiprotozoal activity [23–24]. Their biolo-
gical activity is usually accompanied with cytotoxicity and can mostly
































































































































8 R= OCH3 CRY
9 R= OH CRY-D7
5+64
31 R= OCOCH3
2 R= OH Achillolide-A
Fig. 2. Isolated compounds from dichloromethane extract of A. fragrantissima.
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PAINS problem [25]. Since this structural feature determines both anti-
trypanosomal and cytotoxic activity, [23] we did not consider the
sesquiterpene lactones for further investigations or synthetic optimi-
zations.
The isolated ﬂavonoids Chrysosplenetine 8 and Chrysosplenol-D 9
represented moderate activities with two digit micromolar anti-
trypanosomal activity. Both ﬂavonoids were never reported for their
anti-trypanosomal activity. However, ﬂavonoids are generally known
to exhibit anti-protozoal activity [26] in addition to various other
bioactivities [27]. They are also well known as strong antioxidants
being able to eﬀectively protect against radical toxicity. This is due to
the catechol moiety which can be easily oxidized to the quinones which
often are present in ﬂavonoids. However, quinones deliberately react
with the nucleophilic thiol residues in proteins resulting in cytotoxicity
[28].
Fig. 4. Modiﬁed regions in Pellitorine 10 for SAR study.
Fig. 5. Survival rates of the larvae for compound 26 and 27.
Fig. 3. 1H-1H COSY and HMBC correlations for 13.
Table 1
Bioevaluation of isolated compounds.
Compound Chemical group IC50 [μM]
T.b. brucei
1 Sesquiterpene lactones 3.03 ± 0.06
2 Sesquiterpene lactones 10.97 ± 0.47
3 Sesquiterpene lactones 10.97 ± 0.11
4 Sesquiterpene lactones 27.03 ± 0.13
5 + 6 Sesquiterpene lactones 60.92 ± 0.76
7 Sesquiterpene lactones > 80
8 Flavonoids 30.35 ± 0.23
9 Flavonoids 47.27 ± 0.39
10 Alkamides 30.76 ± 0.08
11 Alkamides 31.05 ± 0.13
12 Alkamides 36.98 ± 0.64
13 Alkamides 40.37 ± 0.21
Pentamidine Dibenzamidine 0.007 ± 0.00
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Table 2
Anti-trypanosomal activity, cytotoxicity, and selectivity indices of compounds 14–40.





14 Methyl > 40 > 100 –
15 Pentyl > 40 > 100 –
16 Pentyl 36.64 ± 0.08 > 100 > 2.7
17 C6H4 Pentyl 34.37 ± 0.10 > 100 > 2.9
18 C6H4 Pentyl 30.73 ± 0.03 > 100 > 3.3
19 C6H4 Hexyloxy 19.82 ± 0.07 81.5 4.1
20 C6H4 Pentyl > 40 – –
21 C6H4 Hexyloxy > 40 – –
22 C6H4 Pentyl 3.90 ± 0.01 24.1
23 C6H4 Hexyloxy 2.16 ± 0.02 48.6 22.5
24 C6H4 Pentyl 3.11 ± 0.01 49.5 15.9
25 C6H4 Hexyl 3.24 ± 0.02 29.5 9.1
26 C6H4 Heptyl 0.72 ± 0.00 14.4 20.1
27 C6H4 Hexyloxy 0.72 ± 0.00 32.9 45.7
28 C6H4 Pentyl 3.74 ± 0.01 48.6 13
29 C6H4 Hexyl 3.31 ± 0.24 18.2 5.5
30 C6H4 Heptyl 2.94 ± 0.02 23.5 8
31 C6H4 Hexyloxy 3.01 ± 0.01 23.8 7.9
32 C6H4 Pentyl 3.36 ± 0.01 44.7 13.3
33 C6H4 Hexyloxy 3.41 ± 0.06 19.1 5.6
34 C6H4 Pentyl 3.89 ± 0.01 50.2 12.9
35 C6H4 Pentyl 31.74 ± 0.29 > 100 > 3.2
36 C6H4 Pentyl 20.77 ± 0.07 49.8 2.4
37 C6H4 Pentyl 32.49 ± 0.07 48.7 1.5
38 C6H4 Pentyl 13.61 ± 0.1 19.1 1.4
39 C6H4 Pentyl 0.48 ± 0.00 5.1 10.6
40 C6H4 Butoxy 0.71 ± 0.00 4.8 6.8
a Sel. Index = (IC50 against microphages J744.1)/(IC50 against T.b. brucei).
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Pellitorine 10 and the alkamides 11, 12, and 13 exhibited anti-
trypanosomal activity with an IC50 range of 30 to 40 μM. Of note,
pellitorine 10 as well as 11 and 12 were previously isolated from A.
ptarmica[22] and reported to have anti-trypanosomal activity against
T.b. rhodesiense.
3.4. Study of structure-activity relationship (SAR) of alkamides
Whereas ﬂavonoids and sesquiterpene lactones are widely known to
have a variety of biological eﬀects [29–30] due to reactive moieties and
their SARs as anti-protozoal agents were explored previously [23,26],
the anti-trypanosomal activity of alkamides remains almost unknown.
Hence, a library of 27 alkamides was synthesized and subjected to
biological testing in order to improve the antitrypanosomal activity and
to derive SAR. The compounds were varied at three key regions of the
structure, namely the amide head, the central core, and the aliphatic
chain (Fig. 4). All 27 compounds were biologically assessed for anti-
trypanosomal activity against T.b. brucei and for cytotoxicity against
macrophages J774.1. Selectivity indices were calculated as the ratio of
IC50 against macrophages J774.1 and the IC50 against T.b. brucei. The
biological data are summarized in Table 2.
Comparing the IC50 values of the compounds diﬀering in length of
the aliphatic chain (R2) revealed the importance of the number of C
atoms for the activity. Compound 14, having a terminal methyl group,
was found to be inactive (IC50 > 40 μM), while both Pellitorine 10 and
the alkamide 16 having a pentyl chain were found to be active at a
concentration level of approx. 30 μM. The presence of one or two
double bonds at positions 1 and/or 2, or an aromatic system, respec-
tively, in the linker region X is also essential for the activity. Compound
15, having a completely saturated chain, was found to be inactive.
Compounds possessing a basic amine moiety in region R1, i.e.22–34,
were highly potent anti-trypanosomal substances with IC50 values in
the range of 0.72 to 3.90 μM. Compounds 26 and 27, having heptyl and
hexyloxy chains, respectively, in region R2 possess the highest activities
in the submicromolar concentration range along with the highest se-
lectivity indices of 20.1 and 45.6, respectively. Interestingly, com-
pounds carrying a morpholine at R1 were found to be inactive; com-
pound 35 having an acetamide moiety has a moderate activity and a
low cytotoxicity, whereas compounds 36–38 bearing aromatic hetero-
cyclic amines have a moderate activity, but a remarkable cytotoxicity
and thus, low selectivity indices. The two bis-amino compounds 39 and
40 exhibited high activities in the submicromolar concentration range
but again a high cytotoxicity was observed.
The toxicity of the most active compounds 26 and 27 was assessed
using Galleria mellonella larvae as an in vivo model. The greater wax
moth Galleria mellonella larvae have been increasingly used as an in vivo
model for assessing the toxicity and eﬃcacy of antimicrobial agents and
studying microbial infections [11,31]. Their ability to survive at phy-
siological temperatures (30 °C or 37 °C), low maintenance costs, easy
handling, and absence of any ethical concerns are some of the most
important advantages of using these larvae for toxicity evaluation and
pharmacokinetics studies [32]. The survival rates of the larvae are re-
presented in Fig. 5, demonstrating that none of the tested concentration
levels (1.25–20 mM) of both compounds induced toxic eﬀects on the
individuals. Also, the occurrence of few deaths observed with the tested
concentration levels was not statistically signiﬁcant, whereas methanol
treatment (positive control) signiﬁcantly led to death of the larvae
(p < 0.0001). Because of the apparent absence of an in vivo toxicity
and the relatively high trypanocidal activity, 26 and 27 can be regarded
as lead compounds.
4. Conclusion
Three groups of natural products having an anti-trypanosomal ac-
tivity were identiﬁed in A. fragrantissima including sesquiterpene lac-
tones, ﬂavonoids, and alkamides. Since the anti-trypanosomal activity
and the SAR of the alkamides were not exclusively studied, a series of
systematically varied alkamides was synthesized. Within this series, the
compounds having heptyl or hexyloxy, respectively, in region R2 and a
basic amine moiety in region R1 were found to be highly active with
high selectivity indices. Notably, no toxicity was observed in an in vivo
model utilizing Galleria mellonella in concentrations up to 20 mM. These
compounds can be regarded as new leads. However, further work has to
be performed to elucidate the mode of action of these compounds.
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